| | FORM | 4 | UNITE | D ST/ | ATE | s s | ECL | | | | | NGE C | OMM | SSION | | | | 1 |
|--|---|--|---|--------------------------|--------------|---|-------------------------------|--|-------------------------|------------------|---|---------------------------------------|--|---|---|-----------------------------------|---|--|
| | | | Washington, D.C. 20549 OMB APPROVAL OMB Number: 3235-0287 OMB Number: 3235-0287 | | | | | | | | | | | | | | | |
| Check Section | TEME | ENT | OF | CH | ANGE | ES IN | VNERS | SHIP | Estir | mated av | erage burd | en | | | | | | |
| Instruc | ions may conti tion 1(b). | iue. 3ee | | Fil | ed pur or | suant r Sect | t to Sec tion 30 | ction 16(a (h) of the | i) of the S Investme | Securi ent Co | ties Exchan | ge Act of 1 of 1940 | 934 | | nour | rs per res | sponse: | 0.5 |
| | | Reporting Person* | | | | | | | | | | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) | | | | | |
| WILSON TROY EDWARD | | | | | | Kura Oncology, Inc. [KURA] | | | | | | | | | X Director 10% Owner | | | |
| (Last) (First) (Middle) | | | | | | 3. Date of Earliest Transaction (Month/Day/Year) | | | | | | | | X Officer (give title Other (speci below) below) | | | | |
| C/O KURA ONCOLOGY, INC. | | | | | 10/06/2020 | | | | | | | | | President and CEO | | | | |
| 12730 H | | 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Indivi | | | | | | | | | ndividual or . | loint/Grou | ın Filina | (Check A | pplicable | | | |
| (Street) | | | | | | | | | | | | | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person | | | | | |
| SAN DIEGO CA 92130 | | | | | _ | | | | | | | | Form filed by More than One Reporting | | | | | |
| (City) | | Person | | | | | | | | | | | | | | | | |
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | | | | | | | | | | | | | | | | | | |
| 1. Title of Security (Instr. 3) | | | | 2. Transaction Date | | | 2A. Deemed Execution Date, | | | | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and | | | | | 6. Ownership Form: Direct | | 7. Nature of Indirect |
| | | | | (Month/Day/Year) | | | r) if any (Month/Day/Year) | | Code (Instr. 8) | | 5) | | | Beneficially Owned Following Reported | | (D) or Indirect (I) (Instr. 4) | | Beneficial Ownership (Instr. 4) |
| | | | | | | | | | Code | v | Amount | (A) or (D) | Price | Transaction (Instr. 3 and | | | | |
| Common | Stock | | | 10/06 | 6/2020 | | | | S ⁽¹⁾ | | 100 | D | \$32 | 206, | 636 | | I | by Araxes Pharma LLC |
| Common Stock | | | | 10/07/2020 | |) | | | S ⁽¹⁾ | | 99,900 | D | \$32 | 3 2 106,736 | | | I | by Araxes Pharma LLC |
| Common Stock | | | | 10/08/2020 | | | | | S ⁽¹⁾ | | 106,73 | 106,736 D | | 0 | | | I | by Araxes Pharma LLC |
| Common Stock | | | | 10/07/2020 | | | | | M ⁽²⁾ | | 4,586 | A | \$6.15 | 32,6 | 582 | 1 | D | |
| Common Stock | | | | 10/07/2020 | | | | | S ⁽²⁾ | | 4,586 | D | \$34 | 28,0 |)96 |] | D | |
| Common Stock | | | | 10/08/2020 | | | | | M ⁽²⁾ | | 50,370 A | | \$6.15 | 78,466 | | j | D | |
| Common Stock | | | | 10/08/2020 | | | | | S ⁽²⁾ | | 50,370 | D | \$34 | 28,096 | | 1 | D | |
| | | | | | | | | | | | | | | | | | | by Red Fish Blue |
| Common Stock | | | | | | | | | | | | | | 1,795,017 | | I | | Fish |
| | | | | | | | | | | | | | | | | | | Revocable Trust |
| | | | Table II - | | | | | | | | bosed of, | | | v Owned | | | | |
| 1. Title of | 2. | 3. Transaction | 3A. Deem | | puts, | cal | - | arrants umber | | | sable and | | | 8. Price of | 9. Numb | or of | 10. | 11. Nature |
| Derivative Security (Instr. 3) | erivative Conversion Date Executio ecurity or Exercise (Month/Day/Year) if any | | | n Date, Transa Code (| | action of (Instr. Derivati Securiti Acquire (A) or Dispose | | ivative urities uired or oosed O) (Instr. | Expiration (Month/I | on Dat | te | of Securit Underlyin Derivative | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | rivative curity Securiti str. 5) Benefic Owned Followi Reporte Transac (Instr. 4 | | Ownersh Form: Direct (D) or Indirec (I) (Instr. 4 | ip of Indirect Beneficial Ownership ct (Instr. 4) |
| | | | | | Code | v | (A) | (D) | Date Exercisa | able | Expiration Date | Title | Amount or Number of Shares | | | | | |
| Option to purchase common stock | \$6.15 | 10/07/2020 | | M ⁽²⁾ | | | | 4,586 | (3) | | 01/22/2027 | Common Stock | 4,586 | \$0.00 152,- | | 435 | D | |
| Option to purchase common stock | \$6.15 10/08/2020 | | M ⁽²⁾ | | | Γ | 50,370 | (3) | | 01/22/2027 | Common Stock | 50,370 | \$0.00 102,0 | | 065 | D | | |

Explanation of Responses:

1. The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2019 and amended on June 8, 2020.

2. The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2019 and amended on December 23, 2019 and June 8, 2020.

3. This option vests in 48 equal monthly installments commencing on January 23, 2017.

Remarks:

SEC Form 4

James Basta, Attorney-in-fact 10/08/2020 for Troy E. Wilson ** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.